<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006461.pub4" GROUP_ID="EYES" ID="320605021509505086" MERGED_FROM="" MODIFIED="2014-07-18 13:54:16 +0100" MODIFIED_BY="Anupa Shah" REVIEW_NO="KATA02" REVMAN_SUB_VERSION="5.3.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-07-18 13:54:16 +0100" MODIFIED_BY="Anupa Shah">
<TITLE>Interventions for strabismic amblyopia</TITLE>
<CONTACT MODIFIED="2014-07-18 13:54:16 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="12144" ROLE="AUTHOR"><FIRST_NAME>Kate</FIRST_NAME><LAST_NAME>Taylor</LAST_NAME><POSITION>Experienced Orthoptist</POSITION><EMAIL_1>kate.taylor@nuth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Ophthalmology</DEPARTMENT><ORGANISATION>Royal Victoria Infirmary</ORGANISATION><ADDRESS_1>Claremont Wing</ADDRESS_1><ADDRESS_2>Queen Victoria Road</ADDRESS_2><CITY>Newcastle upon Tyne</CITY><ZIP>NE1 4LP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 282 5415</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-07-18 13:54:16 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="12144" ROLE="AUTHOR"><FIRST_NAME>Kate</FIRST_NAME><LAST_NAME>Taylor</LAST_NAME><POSITION>Experienced Orthoptist</POSITION><EMAIL_1>kate.taylor@nuth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Ophthalmology</DEPARTMENT><ORGANISATION>Royal Victoria Infirmary</ORGANISATION><ADDRESS_1>Claremont Wing</ADDRESS_1><ADDRESS_2>Queen Victoria Road</ADDRESS_2><CITY>Newcastle upon Tyne</CITY><ZIP>NE1 4LP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 282 5415</PHONE_1></ADDRESS></PERSON><PERSON ID="11239" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Sue</FIRST_NAME><LAST_NAME>Elliott</LAST_NAME><POSITION>Head Orthoptist</POSITION><EMAIL_1>sue.elliott@salisbury.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Ophthalmology Department</DEPARTMENT><ORGANISATION>Salisbury Health Care NHS Trust</ORGANISATION><ADDRESS_1>Salisbury District Hospital</ADDRESS_1><CITY>Salisbury</CITY><ZIP>SP2 8BJ</ZIP><REGION>Wiltshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1722 336262 ext: 4908</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-07-08 20:14:29 +0100" MODIFIED_BY="Anupa  Shah">
<UP_TO_DATE>
<DATE DAY="30" MONTH="1" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="1" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="1" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-07-18 13:51:08 +0100" MODIFIED_BY="Anupa  Shah">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-07-18 13:51:08 +0100" MODIFIED_BY="Anupa  Shah">
<DATE DAY="18" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Issue 7, 2014: One potential study identified (<LINK REF="STD-Alotaibi-2012" TYPE="STUDY">Alotaibi 2012</LINK>) but awaiting further information before including it in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-07-18 13:50:52 +0100" MODIFIED_BY="Anupa  Shah">
<DATE DAY="18" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Issue 7, 2014: Electronic searches updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-07-18 13:46:18 +0100" MODIFIED_BY="Anupa  Shah">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-07-18 13:46:18 +0100" MODIFIED_BY="Anupa  Shah">
<DATE DAY="29" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Lead author's surname has changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-07-18 13:46:16 +0100" MODIFIED_BY="Anupa  Shah">
<DATE DAY="27" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Issue 8 2011: Updated searches yielded no new trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-06-27 09:49:04 +0100" MODIFIED_BY="Anupa Shah">
<DATE DAY="12" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Issue 1, 2010: Updated searches yielded one new trial for inclusion in the review (<LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-06-19 10:25:13 +0100" MODIFIED_BY="Anupa Shah">
<DATE DAY="18" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="12" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-07-08 20:12:35 +0100" MODIFIED_BY="Anupa  Shah">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-07-08 20:12:35 +0100" MODIFIED_BY="Anupa  Shah">
<SOURCE MODIFIED="2014-07-08 20:12:35 +0100" MODIFIED_BY="Anupa  Shah">
<NAME>National Institute of Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the NIHR to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-07-16 19:22:47 +0100" MODIFIED_BY="Anupa  Shah">
<SUMMARY MODIFIED="2014-07-16 19:22:47 +0100" MODIFIED_BY="Anupa  Shah">
<TITLE MODIFIED="2014-07-08 20:08:42 +0100" MODIFIED_BY="Anupa  Shah">Treatment of amblyopia (lazy eye) caused by strabismus (squint) with patching or optical treatment (glasses or penalisation) or both</TITLE>
<SUMMARY_BODY MODIFIED="2014-07-16 19:22:47 +0100" MODIFIED_BY="Anupa  Shah">
<P>Review question: Treatment of amblyopia (lazy eye) caused by strabismus (squint) with patching or optical treatment (glasses or penalisation) or both.<BR/>
<BR/>Background: Amblyopia is a common childhood condition which causes a reduction in vision of one or both eyes which is not caused by any eye disease. Amblyopia can be caused by the presence of a squint (misalignment of the eyes where one eye may turn inwards, outwards, upwards or downwards). This review aims to look at the treatment of reduced vision caused by the presence of a squint, not the treatment of the squint itself.<BR/>
<BR/>Search date: Searches were last run 30 January 2014.<BR/>
<BR/>Study characteristics: Three randomised controlled trials (RCTs) conducted in the United States were included in this review.<BR/>
<BR/>Key results: The results of one of these trials indicate that patching therapy combined with any necessary glasses is more effective than glasses alone in the treatment of this condition. Two of the trials analysed the role of adding near activities to supplement patching therapy. These trials suggest there may be benefit to adding near activities to prescribed occlusion regime. No trial examining the role of optical penalisation (altering glasses strength) or using partial occlusion (frosted lens opposed to a patch) was found. The effectiveness of optical penalisation and partial occlusion for the treatment of strabismic amblyopia is unknown.<BR/>
<BR/>Quality of the evidence: The quality of the available evidence is high.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-07-16 19:20:59 +0100" MODIFIED_BY="Anupa  Shah">
<ABS_BACKGROUND>
<P>Amblyopia is reduced visual acuity in one or both eyes in the absence of any demonstrable abnormality of the visual pathway. It is not immediately resolved by the correction of refractive error. Strabismus develops in approximately 5% to 8% of the general population. The aim of treatment for amblyopia is to obtain the best possible level of vision in the amblyopic eye. Different treatment options were examined within the review. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-04 13:45:00 +0000" MODIFIED_BY="Anupa Shah">
<P>By reviewing the available evidence we wanted to establish the most effective treatment for strabismic amblyopia. In particular this review aimed to examine the impact of conventional occlusion therapy for strabismic amblyopia and to analyse the role of partial occlusion and optical penalisation for strabismic amblyopia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-07-03 11:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2013, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to January 2014), EMBASE (January 1980 to January 2014), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to January 2014), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 30 January 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included randomised controlled trials (RCTs) for the treatment of strabismic amblyopia including participants of any age. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-09-29 12:39:00 +0100" MODIFIED_BY="Anupa Shah">
<P>Two authors working independently extracted and entered data into Review Manager 5 and then independently checked the data for errors.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-07-16 19:20:59 +0100" MODIFIED_BY="Anupa  Shah">
<P>We included three RCTs in this review. The studies reported mean logMAR visual acuity achieved. Mean difference in visual acuity was calculated. When comparing conventional part-time occlusion (with any necessary glasses), <A HREF="PEDIG 2006">PEDIG 2006</A> reported that this treatment was more beneficial than glasses alone for strabismic amblyopia; the mean difference between groups was -0.18 LogMAR (statistically significant 95% confidence interval (CI) -0.32 to -0.04). Supplementing occlusion therapy with near activities may produce a better visual outcome compared to non-near activities after four weeks of treatment (<A HREF="PEDIG 2005">PEDIG 2005</A>). The results of the pilot study showed mean difference between groups was -0.17 LogMAR (95% CI -0.53 to 0.19). Results from a larger RCT (<A HREF="PEDIG 2008">PEDIG 2008</A>) are now available, showing that supplementing occlusion therapy with near activities may produce a better visual outcome after eight weeks of treatment; the mean difference between groups was -0.02 LogMAR (95% CI -0.10 to 0.06). One further article ia awaiting assessment as in its current format there is insufficient information to include (<A HREF="Alotaibi 2012">Alotaibi 2012</A>).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-09-29 12:40:14 +0100" MODIFIED_BY="Anupa Shah">
<P>Occlusion, whilst wearing necessary refractive correction, appears to be more effective than refractive correction alone in the treatment of strabismic amblyopia. The benefit of combining near activities with occlusion is unproven. No RCTs were found that assessed the role of either partial occlusion or optical penalisation to refractive correction for strabismic amblyopia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-07-03 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-07-03 14:29:14 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-07-03 14:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>Amblyopia (lazy eye) is reduced visual acuity in one or both eyes in the absence of a demonstrable abnormality of the visual pathway. It is not immediately resolved by the correction of any refractive error.</P>
<P>Amblyopia develops only during the critical period when the visual system is vulnerable to amblyogenic factors such as strabismus (<LINK REF="REF-Ansons-2001" TYPE="REFERENCE">Ansons 2001</LINK>). It is most marked in children under the age of two years (<LINK REF="REF-Awaya-1987" TYPE="REFERENCE">Awaya 1987</LINK>). Treatment is thought to be effective only during this critical period which varies for different types of amblyopia.</P>
<P>There are five types of amblyopia, which are classified by causative factors:<BR/>
</P>
<UL>
<LI>Strabismic (caused by misalignment of the eyes);</LI>
<LI>Stimulus deprivation (reduced vision occurring secondary to an obstacle in the anterior visual pathway);</LI>
<LI>Anisometropic (a difference in the refractive (focusing) error of both eyes);</LI>
<LI>Ametropic (significant refractive error of both eyes);</LI>
<LI>Meridional (astigmatism of both eyes).</LI>
</UL>
<P>Strabismus (squint) is a misalignment of the eyes in which the visual axes deviate from bifoveal fixation, that is, one eye will look straight ahead whilst the other turns inwards, outwards, up or down. Strabismus may be constant or intermittent (<LINK REF="REF-RCOphth-2002" TYPE="REFERENCE">RCOphth 2002</LINK>).</P>
<P>Any of the other types of amblyopia may co-exist with strabismic amblyopia. Each type of amblyopia is the subject of a Cochrane review (<LINK REF="REF-Antonio_x002d_Santos-2014" TYPE="REFERENCE">Antonio-Santos 2014</LINK>; <LINK REF="REF-Li-2009" TYPE="REFERENCE">Li 2009</LINK>; <LINK REF="REF-Taylor-2012" TYPE="REFERENCE">Taylor 2012</LINK>).</P>
<P>This review will concentrate on strabismic amblyopia in isolation to prevent overlap with existing reviews.</P>
<SUBSECTION>
<HEADING LEVEL="5">Epidemiology</HEADING>
<P>Strabismus develops in approximately 5% to 8% of the general population (<LINK REF="REF-Rowe-2004" TYPE="REFERENCE">Rowe 2004</LINK>). If either parent has strabismus the risk of the child being affected is four times greater than that of a child of parents without strabismus. It has been found that 65% of affected children have a close relative with a strabismus (<LINK REF="REF-Ansons-2001" TYPE="REFERENCE">Ansons 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Presentation and diagnosis</HEADING>
<P>The majority of children present with strabismic amblyopia when a parent or a health professional becomes concerned about the appearance of the strabismus. The degree of strabismus may range from very small, for example, microtropia (five degrees or less) with useful binocular single vision (BSV), to more marked, cosmetically obtrusive misalignment.</P>
<P>There are five main stages in the diagnosis of strabismic amblyopia.<BR/>1. The visual acuity of each eye is tested using an age and ability-appropriate test.<BR/>2. Strabismus is detected by performing a cover test. This is an objective dissociative test in which the examiner observes the child's eyes whilst fixation is maintained and each eye is in turn covered and uncovered (<LINK REF="REF-Rowe-2004" TYPE="REFERENCE">Rowe 2004</LINK>). Amblyopia is unlikely to be present if there is free alternation of the strabismus from one eye to the other.<BR/>3. External examination to identify any pathology, for example, ptosis (drooping of the eyelid).<BR/>4. Refraction (test for glasses), fundus and media check. Cycloplegic eye drops that temporarily paralyse the focusing muscle within the eye and dilate the pupil need to be used for these examinations. Glasses will be prescribed if necessary. A fundus and media check will determine whether there is any ocular pathology.<BR/>5. Re-testing the visual acuity with any refractive correction in place. It is likely that there will be some improvement if glasses have been worn as instructed. <LINK REF="REF-Stewart-2004" TYPE="REFERENCE">Stewart 2004</LINK> emphasised the importance of refractive adaptation, that is, allowing a child to 'settle' into his or her glasses prior to beginning occlusion or penalisation therapy to avoid unnecessary occlusion. Refractive adaptation is now seen as a distinct component of amblyopia treatment.</P>
<P>There is a lack of clarity as to what constitutes a significant interocular difference in visual acuity and there is little evidence as to what is 'normal' on many of the commonly used visual acuity tests at different ages. We decided to define amblyopia as the best-corrected visual acuity (BCVA) of worse than 6/9 on a Snellen based test, or 0.2 on a LogMAR based test (or equivalent) of the amblyopic eye. The fellow, non-amblyopic eye will have a best-corrected visual acuity of 6/9 Snellen or 0.2 LogMAR or better.</P>
<P>This review included both LogMAR and Snellen-based optotype-based measures of visual acuity.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2009-11-04 14:24:59 +0000" MODIFIED_BY="Anupa Shah">
<P>The methods of treatment for amblyopia are based on correcting any refractive error and then preventing use of the better eye in order to promote use of the amblyopic eye. This can be done in the following ways:<BR/>
</P>
<UL>
<LI>Total occlusion: total to form and light (usually using conventional patching or less frequently the use of an occlusive contact lens).</LI>
<LI>Partial occlusion, including optical penalisation: reduction in form vision. Frosting the lens or altering the spectacle lens to blur the image in front of the non-amblyopic eye can achieve this.</LI>
<LI>Pharmacological: cycloplegic drugs are used to temporarily blur the vision of the good eye.</LI>
<LI>A combination of these options.</LI>
</UL>
<P>Total occlusion of the non-amblyopic eye remains the mainstay of treatment for strabismic amblyopia. The effectiveness of this form of treatment has been questioned because of a lack of randomised controlled trials (RCTs) (<LINK REF="REF-Cleary-2000" TYPE="REFERENCE">Cleary 2000</LINK>).</P>
<P>All pharmacological interventions are excluded from this review as they are part of a separate Cochrane review (<LINK REF="REF-Li-2009" TYPE="REFERENCE">Li 2009</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2009-09-29 12:40:43 +0100" MODIFIED_BY="Anupa Shah">
<P>Occlusion, either partial or total, works by degrading the quality of the image seen by the non-amblyopic eye. Total occlusion removes all light and form seen by the non-amblyopic eye whilst partial occlusion still allows light to enter the eye.</P>
<SUBSECTION>
<HEADING LEVEL="5">Factors affecting outcome</HEADING>
<P>The aim of treatment for amblyopia is to obtain the best possible level of vision in the amblyopic eye. Factors thought to influence the treatment outcome include age at onset of amblyopia, age when treatment commenced, type of amblyopia and presenting level of visual acuity, with more severely reduced acuity possibly having a poorer prognosis. <LINK REF="REF-Epelbaum-1993" TYPE="REFERENCE">Epelbaum 1993</LINK> reported a maximum improvement in strabismic amblyopia if treatment was started before three years of age, but it has also been suggested that improvement is possible in older children (<LINK REF="REF-Mintz_x002d_Hittner-2000" TYPE="REFERENCE">Mintz-Hittner 2000</LINK>; <LINK REF="REF-Mohan-2004" TYPE="REFERENCE">Mohan 2004</LINK>).</P>
<P>Non-compliance with treatment also influences the success of treatment. <LINK REF="REF-Newsham-2000" TYPE="REFERENCE">Newsham 2000</LINK> found that poor parental knowledge regarding the critical period and correct implementation of the treatment regimen led to non-concordance and therefore poorer treatment outcomes.</P>
<P>In certain circumstances it is not possible to achieve equal vision. Co-existence of strabismus and anisometropia is known to constitute a barrier to the achievement of 'normal' visual acuity and therefore increase the likelihood of a poor vision outcome (<LINK REF="REF-Cleary-2000" TYPE="REFERENCE">Cleary 2000</LINK>). However, it is not always known why visual acuity does not respond to treatment.</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2014-06-17 13:46:25 +0100" MODIFIED_BY="[Empty name]">
<P>The rationale for treatment of unilateral amblyopia is that an individual with poor visual acuity due to untreated amblyopia may be disadvantaged should they lose the vision in their better eye. The projected lifetime risk of this occurring is approximately 3% (<LINK REF="REF-Rahi-2002" TYPE="REFERENCE">Rahi 2002</LINK>). Poor vision, even in one eye, may also be a barrier to certain careers (<LINK REF="REF-Taylor-1995" TYPE="REFERENCE">Taylor 1995</LINK>). Good bilateral and binocular vision is a requirement for some employment such as the armed forces, some police work and driving heavy goods vehicles.</P>
<P>There is a lack of standardisation as to the type and amount of occlusion given for any type of amblyopia, including strabismic (<LINK REF="REF-Cleary-2000" TYPE="REFERENCE">Cleary 2000</LINK>; <LINK REF="REF-Tan-2003" TYPE="REFERENCE">Tan 2003</LINK>). Occlusion may range from full-time (all waking hours) to just one hour per day depending upon the management regime followed. Therefore this review aims to investigate the effectiveness of treatment for strabismic amblyopia. The results of this review will be relevant to eye professionals, affected children and their parents.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-06-23 13:34:42 +0100" MODIFIED_BY="Anupa Shah">
<P>By reviewing the available evidence we wanted to establish the most effective treatment for strabismic amblyopia. In particular, this review aimed to:</P>
<P>1. Examine the impact of conventional occlusion therapy on the outcome of treatment of strabismic amblyopia; and<BR/>2. Analyse the roles of partial occlusion and optical penalisation for strabismic amblyopia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-07-03 11:45:32 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-06-27 10:01:23 +0100" MODIFIED_BY="Anupa Shah">
<CRIT_STUDIES>
<P>This review included RCTs of treatment for strabismic amblyopia. We imposed no language or date restrictions on the trials included. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-09-18 11:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials with participants of any age, diagnosed with strabismic amblyopia.</P>
<P>The criteria for diagnosis was:<BR/>1. Presence of a manifest strabismus diagnosed by cover test (with any necessary refractive correction in place);<BR/>2. Corrected visual acuity in the amblyopic eye of worse than 6/9 (Snellen) or 0.2 (LogMAR) or equivalent, measured on an age-appropriate test;<BR/>3. Corrected visual acuity in the non-amblyopic eye of 6/9 (Snellen) or 0.2 (LogMAR) or better measured on an age-appropriate test.</P>
<P>All participants had undergone cycloplegic refraction and had corrected visual acuity assessed using an age-appropriate test prior to diagnosis. All participants were allowed a period of refractive adaptation as defined by each study to settle into glasses prescribed prior to being enrolled into a study. The results of all trials were analysed with the refractive adaptation time period in mind and results discussed in this context.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-11-04 14:24:59 +0000" MODIFIED_BY="Anupa Shah">
<P>We considered trials that included the use of the following as primary interventions:</P>
<P>1. Full-time total occlusion (more than six hours per day);<BR/>2. Part-time total occlusion (six hours or less per day);<BR/>3. Partial occlusion (any regime);<BR/>4. Optical penalisation (alteration of glasses lens in front of the better seeing eye in order to blur vision).</P>
<P>All topical pharmacological interventions were excluded as they are the subject of a separate Cochrane review (<LINK REF="REF-Li-2009" TYPE="REFERENCE">Li 2009</LINK>).</P>
<P>The comparisons examined within this review were:<BR/>1. Conventional full-time total occlusion versus glasses alone/observation;<BR/>2. Conventional part-time total occlusion versus glasses alone/observation;<BR/>3. Partial occlusion versus glasses alone/observation;<BR/>4. Optical penalisation versus glasses alone/observation;<BR/>5. Occlusion with prescribed near activities versus occlusion without near activities/distance activities.</P>
<P>The 'observation' group included participants wearing any refractive correction but not any of the above treatments.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-06-27 10:01:23 +0100" MODIFIED_BY="Anupa Shah">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-11-02 16:24:15 +0000" MODIFIED_BY="Anupa Shah">
<P>The primary outcome for this review was change in BCVA of the amblyopic eye on an age specific test at 12 months from cessation of treatment.</P>
<P>As LogMAR data was available from start to finish of treatment we analysed the degree of change in visual acuity. This produced continuous data, hence analysis of the weighted mean difference was carried out to summarise the result.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-06-27 10:01:23 +0100" MODIFIED_BY="Anupa Shah">
<P>The secondary outcome for this review was best-corrected final visual acuity at any time point during or after cessation of treatment.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>Information reported in studies regarding adverse events was divided into mild or severe:</P>
<P>
<I>Mild </I>
<BR/>
</P>
<UL>
<LI>Psychological effects which do not require treatment.</LI>
<LI>Allergies, for example skin irritations to patch.</LI>
<LI>Disorientation if visual acuity is very poor in the amblyopic eye.</LI>
</UL>
<P>
<I>Severe </I>
<BR/>
</P>
<UL>
<LI>Psychological effects which require further investigation or treatment.</LI>
<LI>Intractable diplopia (double vision): diplopia which is caused by the loss of suppression through occlusion therapy where binocular single vision cannot be achieved with prisms and the patient cannot re-suppress. This leads to permanent double vision.</LI>
<LI>Occlusion amblyopia: reduction in visual acuity of the non-amblyopic eye, increase in size of strabismus or dissociation of strabismus.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life measures</HEADING>
<UL>
<LI>We reported any quality of life measures associated with having residual amblyopia.</LI>
<LI>We described any quality of life measures relating to the treatment of amblyopia.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Economic data</HEADING>
<P>Any data reporting the cost of treating amblyopia were included.</P>
<P>
<I>
<B>Follow up</B>
</I>
<BR/>The follow-up period for all included trials was likely to vary. The results were reported in the context of the actual follow-up period.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-07-03 11:41:35 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-07-03 11:41:35 +0100" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2013, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to January 2014), EMBASE (January 1980 to January 2014), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to January 2014), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials.We last searched the electronic databases on 30 January 2014.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), <I>m</I>RCT (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), ClinicalTrials.gov (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>), and the ICTRP (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-18 17:09:17 +0100" MODIFIED_BY="Anupa Shah">
<P>We manually searched the reference lists of the trials included in the review for additional trials. We did not handsearch journals or conference proceedings specifically for this review.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-07-03 11:45:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-04-15 13:43:52 +0100" MODIFIED_BY="Kate Shotton">
<P>Both review authors undertook independent assessment of abstracts to ascertain which studies met the inclusion criteria for the review. Abstracts were labelled as included, unclear or excluded. Full copies of all included and unclear studies were obtained and the two review authors once again worked independently to determine which studies met the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-07-03 11:45:32 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors working independently extracted data from included trials using a data collection form. Where possible, data were collected directly from the published paper but in some cases extra data were provided by trial co-ordinators (<LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK>; <LINK REF="STD-PEDIG-2006" TYPE="STUDY">PEDIG 2006</LINK>; <LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK>). For <LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK> and <LINK REF="STD-PEDIG-2006" TYPE="STUDY">PEDIG 2006</LINK>, data were entered into Revman using the double data entry facility to check for errors. This facility was not available in RevMan 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). For <LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK> data were extracted by the authors independently and results compared. Data were then entered into RevMan by one author (KS) and checked by the other (SE).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-06-27 10:03:01 +0100" MODIFIED_BY="Anupa Shah">
<P>Once studies had been identified as meeting the inclusion criteria the two authors assessed them for methodological quality according to Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>The following parameters were considered: generation of the random sequence, masking (blinding) of examiners, allocation concealment and completeness of follow up. In addition the authors considered whether there appeared to be any evidence of selective reporting of results or other sources of bias.</P>
<P>We graded each parameter of trial quality as 'low risk of bias', 'high risk of bias' or 'unclear'. Where any parameter was graded as unclear we contacted trial authors for clarification.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-06-27 10:03:40 +0100" MODIFIED_BY="Anupa Shah">
<P>Data analysis followed the guidelines in Chapter 9 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). For continuous outcomes, we calculated the weighted mean difference.</P>
<P>Meta-analysis was not performed as insufficient data was present for each comparison. If in future updates it is possible to carry out a meta-analysis, we will use a fixed-effect model where the number of trials is less than three.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-11-04 14:46:23 +0000" MODIFIED_BY="Anupa Shah">
<P>Sensitivity analysis was planned to assess how robust our review results are. In updates of the review we will continue to:<BR/>1. Exclude studies of lower methodological quality;<BR/>2. Exclude unpublished studies.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-07-03 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-07-03 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-07-03 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<P>The electronic searches found 771 titles and abstracts. We screened the titles and abstracts according to the criteria outlined above and identified 16 potential trial reports. After discussion, we decided to obtain the full-text of eight trials.</P>
<P>An update search was done in November 2009 which yielded a further 138 references. The Trials Search Co-ordinator (TSC) scanned the search results and removed any references which were not relevant to the scope of the review. A total of 44 references were screened against the inclusion criteria for the review and we obtained the full-text of one report of a trial (<LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK>).</P>
<P>Updated searches were run in June 2011. The electronic searches yielded a total of 184 titles and abstracts. After deduplication the TSC scanned 130 records and discarded 75 records as they were not relevant to the scope of the review. Both authors independently screened the title and abstracts of the remaining 55 references and it was deemed no new trials met the inclusion criteria of the review. We excluded one trial (<LINK REF="STD-PEDIG-2010" TYPE="STUDY">PEDIG 2010</LINK>).</P>
<P>An update search run in January 2014 identified a further 276 references (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The Trials Search Co-ordinator removed 68 duplicates and screened the remaining 208 references, of which 157 were not relevant to the scope of the review. We reviewed the remaining 51 references and discarded 50 reports as not relevant. We obtained one full-text report for potential inclusion in the review (<LINK REF="STD-Alotaibi-2012" TYPE="STUDY">Alotaibi 2012</LINK>) however insufficient information was available in the published article to assess if the trial was eligible for inclusion. We contacted the authors of the manuscript but to date no reply has been received. The article has therefore been classified as 'awaiting assessment'. Should further information become available then the article will be reassessed.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-06-27 10:05:57 +0100" MODIFIED_BY="Anupa Shah">
<P>We included three studies in this review. See the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table for more information on each study.</P>
<P>
<LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK>
<BR/>This pilot study (leading to the full study reported in <LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK>) included 64 participants aged between three and seven years of age. All children had been diagnosed with anisometropic, strabismic or mixed amblyopia. The authors were able to provide data on the 20 participants diagnosed with strabismic amblyopia as defined within this review. All study participants with vision ranging from 0.300 to 1.300 LogMAR were randomised to receive two hours of daily occlusion with near or distance activities. Data on the 20 participants with strabismic amblyopia was extracted as a subgroup of the total randomised population and therefore may not represent a truly randomised comparison. Compliance to prescribed treatment was assessed via parental diaries and weekly telephone calls. Visual acuity in the amblyopic eye was reported after four weeks of treatment.</P>
<P>
<LINK REF="STD-PEDIG-2006" TYPE="STUDY">PEDIG 2006</LINK>
<BR/>This trial randomised 180 participants to either two hours of daily occlusion with glasses or to a glasses only treatment group. All participants had been diagnosed with moderate (0.300 to 0.600 LogMAR) or severe (0.700 to 1.300 LogMAR) amblyopia and were aged between three and seven years. The main outcome measure of the trial was best-corrected vision in the amblyopic eye after five weeks of treatment.</P>
<P>Participants who required refractive correction entered a spectacle run-in phase of the trial prior to treatment. Optimal refractive correction was prescribed and worn full-time until vision in the amblyopic eye stabilised. Participants were then randomised into a glasses only group or occlusion group. The trial was designed to assess whether the visual acuity of the amblyopic eye would improve more in the occlusion group compared to the glasses only group.</P>
<P>Of the 180 participants included within the study, 39 had strabismic amblyopia as defined within this review. Data on these 39 participants with strabismic amblyopia was extracted as a subgroup of the total randomised population and therefore may not represent a truly randomised comparison. The authors were able to provide visual acuity outcomes for these participants at the five-week examination point.</P>
<P>
<LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK>
<BR/>This trial included 425 participants aged between three and seven years of age, diagnosed with amblyopia (0.300 to 1.300 LogMAR) caused by anisometropia, strabismus or both. Participants were randomised to receive two hours of daily occlusion with near activities or two hours of daily occlusion with distance activities. The main outcome of this trial was visual acuity in the amblyopic eye after eight weeks of treatment. Participants who required any refractive correction were prescribed glasses. Correction was worn for a minimum of 16 weeks or until no documented improvement in visual acuity of the amblyopic eye was reported for two consecutive visits. Compliance to treatment was documented via parental diaries used to document the numbers of hours patched per day and the activities carried out whilst occluded.</P>
<P>Of the included participants, 130 were defined as having strabismic amblyopia and eligible for inclusion within this review. Data on these participants was extracted as a subgroup of the total randomised population. The authors were able to provide data for these participants.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-06-27 10:06:18 +0100" MODIFIED_BY="Anupa Shah">
<P>Seven trials (<LINK REF="STD-Awan-2005" TYPE="STUDY">Awan 2005</LINK>; <LINK REF="STD-PEDIG-2003a" TYPE="STUDY">PEDIG 2003a</LINK>; <LINK REF="STD-PEDIG-2003b" TYPE="STUDY">PEDIG 2003b</LINK>; <LINK REF="STD-PEDIG-2005b" TYPE="STUDY">PEDIG 2005b</LINK>; <LINK REF="STD-PEDIG-2007" TYPE="STUDY">PEDIG 2007</LINK>; <LINK REF="STD-PEDIG-2010" TYPE="STUDY">PEDIG 2010</LINK>; <LINK REF="STD-Stewart-2007" TYPE="STUDY">Stewart 2007</LINK>) have been excluded from the review and reasons for exclusion are documented in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-03 11:59:01 +0100" MODIFIED_BY="[Empty name]">
<P>For full methodological quality and assessment on risk of bias please see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-11-04 14:53:39 +0000" MODIFIED_BY="Anupa Shah">
<P>The three included trials provided data for two separate comparisons within the review. The results for each comparison are summarised below.</P>
<SUBSECTION>
<HEADING LEVEL="5">1. Occlusion with prescribed near activities versus occlusion with non-near activities</HEADING>
<P>Two studies (<LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK>; <LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK>) were included for this comparison (<I>see</I> <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). <LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK> is a pilot study comparing prescribed near and non-near activities whilst carrying out occlusion therapy and <LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK> is the follow-on trial.</P>
<P>
<LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK> included 64 children aged between three to seven years, however, only 20 participants were diagnosed with strabismic amblyopia as defined within the review. As randomisation was not stratified according to the type of amblyopia, these participants represent a subgroup within the trial. The authors were contacted and the information regarding these 20 participants was analysed. All participants in the trials were asked to carry out two hours of daily occlusion. Participants were then randomised into carrying out near or non-near (distance) activities for a period of four weeks. Both a telephone interview and a daily diary assessed compliance to treatment. At the 4 week outcome assessment, the near activities group (n = 12) recorded a mean visual acuity of 0.38 LogMAR (0.17 standard deviation (SD)) and the non-near group (n = 8) recorded a mean visual acuity of 0.55 LogMAR (0.50 SD) at the masked examination. The mean difference is therefore -0.17 LogMAR (95% confidence interval (CI) -0.53 to 0.19). Overall (for all included participants), the results of this pilot trial suggested that there may be some benefit from supplementing occlusion with near activities and so a full trial was conducted.</P>
<P>
<LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK> included 425 participants in total of which 130 were diagnosed with strabismic amblyopia as defined in this review. These participants represent a subgroup of the total of the randomised population. Glasses were prescribed for full-time wear until vision stabilised or 16 weeks. Participants were then prescribed two hours daily occlusion randomised to be supplemented with either near activities or distance activities. Examples of near activities included homework, arts and crafts, computer games and writing and reading. Examples of distance activities included playing with remote control toys, television and general playing. Compliance to treatment was assessed via parental diaries and weekly telephone calls. Occlusion therapy with near activities or with distance activities was prescribed for 17 weeks. The primary outcome for the review was visual acuity at the eight week exam. It is possible that some participants may have continued to have a change in their visual acuity after the eight week outcome assessment. The near activities group (n = 65) recorded a mean visual acuity of 0.331 LogMAR (0.23 SD) at outcome and the distance group (n = 65) recorded a mean visual acuity of 0.350 LogMAR (0.243 SD). The mean difference was calculated to be -0.02 LogMAR (95% CI -0.10 to 0.06), showing no statistical significance between the two treatments for participants with strabismic amblyopia. This is consistent with the findings of the trial when examining all types and severity of amblyopia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Conventional part-time occlusion versus glasses</HEADING>
<P>One study (<LINK REF="STD-PEDIG-2006" TYPE="STUDY">PEDIG 2006</LINK>) was included for this comparison (<I>see </I>
<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). This trial compared two hours of daily occlusion to a control group. The control group were wearing any refractive correction necessary but undergoing no other treatment.</P>
<P>This prospective trial included 180 children aged between three to seven years diagnosed with amblyopia. Thirty-nine participants were diagnosed with strabismic amblyopia and were eligible for inclusion in this review. As for the previous trials, randomisation was not stratified according to the type of amblyopia, therefore these patients also represent a subgroup within the RCT.</P>
<P>All children included were prescribed the necessary refractive correction for a minimum of 16 weeks before being enrolled within the randomised phase of the trial.</P>
<P>The primary outcome for this trial was vision in the amblyopic eye at the five week masked examination. This examination was carried out for 98% of the participants in the patching group and 95% of the participants in the control group. At this masked examination, the mean visual acuity for the treatment group (n = 19) was recorded as 0.33 LogMAR (0.15 SD) and for the control group (n = 20), 0.51 LogMAR (0.29 SD). The mean difference was therefore calculated as -0.18 LogMAR (95% CI -0.32 to -0.04), which is statistically significant.</P>
<P>
<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> shows that for the participants in this trial, two hours daily occlusion combined with necessary refractive correction is more beneficial than refractive correction alone for strabismic amblyopia. All levels of amblyopia from 20/400 (6/120) to 20/40 (6/12) were included in this trial.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-06-27 10:07:23 +0100" MODIFIED_BY="Anupa Shah">
<P>Occlusion therapy for amblyopia is prescribed in order to reverse amblyopia in young children, however, the number of hours prescribed varies widely from practitioner to practitioner and country to country (<LINK REF="REF-Mazow-2000" TYPE="REFERENCE">Mazow 2000</LINK>; <LINK REF="REF-Tan-2003" TYPE="REFERENCE">Tan 2003</LINK>). Data from the three studies included in this review provide some evidence of the effectiveness of treatments for strabismic amblyopia but this evidence is currently limited and there remains a need for more robust data on optimal treatment for this condition. It should also be noted that for all included trials within this review only a subgroup of the participants were eligible for inclusion and therefore there may not be sufficient power to show an effect.</P>
<SUBSECTION>
<HEADING LEVEL="5">Occlusion versus glasses</HEADING>
<P>One trial was included for this comparison. <LINK REF="STD-PEDIG-2006" TYPE="STUDY">PEDIG 2006</LINK> concluded that occlusion with necessary refractive correction was more effective than glasses alone for the treatment of strabismic amblyopia. It is important to remember that the results of this trial are reported after five weeks of treatment and this has important implications for the interpretation of the results. Reported acuities are unlikely to reflect optimal treatment effect but rather show the difference between the two treatments at the five-week outcome. In addition, there are no long-term data available to assess if the treatment effect is sustained once treatment ceases.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Prescribed near versus non-near activities to supplement occlusion</HEADING>
<P>Two RCTs were found that assessed the role of near activities as a supplement to occlusion therapy. <LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK> showed that for children undergoing two hours daily occlusion for unilateral strabismic amblyopia the vision outcome appeared better, on average (although not statistically significant), in those who were instructed to carry out near activities. This pilot trial included participants with all levels of amblyopia from 20/400 (60/120) to 20/40 (6/12) treated for four weeks. Only part of the data set of the full trial is included within the review as not all participants met the inclusion criteria. <LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK> also compared near activities to distance activities with two hours daily prescribed occlusion. The trial included participants with all types and levels of amblyopia. Data provided by the trial organisers on a subgroup of participants diagnosed with strabismic amblyopia showed a minimal improvement compared to vision in the near activities group after eight weeks of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Partial occlusion and optical penalisation</HEADING>
<P>No RCTs were found that assessed the role of either partial occlusion or optical penalisation to glasses alone for strabismic amblyopia. In order to assess their effectiveness a RCT needs to be carried out. One trial comparing partial occlusion (Bangerter filters) to conventional occlusion has been excluded from this review (<LINK REF="STD-PEDIG-2010" TYPE="STUDY">PEDIG 2010</LINK>). This trial included 186 children aged between three and seven years with moderate amblyopia (0.300 to 0.600) of all types. The trial concluded that similar results were produced by both treatment however as this trial did not compare visual acuity outcomes to glasses wear alone it did not meet the inclusion criteria of this review.<BR/>
<I>
<BR/>
</I>
<B>Factors thought to affect outcomes </B>
<BR/>
</P>
<UL>
<LI>Age at onset: All studies within this review included children aged between three to seven years. Treatment is deemed to be more effective during the sensitive period. Currently no RCT is available examining the role of occlusion treatment in those over the age of seven years with strabismic amblyopia.</LI>
<LI>Age at commencement of treatment: All three studies in this review included children between the ages of three to seven years. Several case reports comment on the treatment of strabismic amblyopia in older children. <LINK REF="REF-Park-2004" TYPE="REFERENCE">Park 2004</LINK> described two children aged 10 and 12 years that underwent a regime of full-time occlusion followed by part-time occlusion for several months. Both children improved to a satisfactory level of vision. <LINK REF="REF-Mintz_x002d_Hittner-2000" TYPE="REFERENCE">Mintz-Hittner 2000</LINK> reported a series of nine strabismic amblyopia patients that underwent a variety of treatments from occlusion to the use of an occlusive contact lens. All patients in the series showed an improved level of vision, however, there was no control treatment or randomisation in these studies.</LI>
<LI>Type of amblyopia: All trial participants included within this review were diagnosed with strabismic amblyopia as defined previously within this review. Separate Cochrane reviews are available that assess the treatment options for stimulus deprivation amblyopia and refractive amblyopia.</LI>
<LI>Presenting visual acuity: All participants included within the review had a starting acuity in the amblyopic eye of 20/40 to 20/400 (6/12 to 6/120, 0.300 to 1.000). This is a wide range of acuities from mild amblyopia to severe amblyopia. <LINK REF="STD-PEDIG-2006" TYPE="STUDY">PEDIG 2006</LINK> and <LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK> carried out a subgroup analysis to analyse moderate and severe amblyopia separately. The authors reported no difference in the level of improvement in visual acuity. <LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK> carried out subgroup analyses for moderate and severe amblyopia; this showed that participants (all types of amblyopia) with the worse starting acuity (20/100, 6/30, 0.700 or worse) improved more with the near activities compared to the non-near activities.</LI>
<LI>Compliance: <LINK REF="STD-PEDIG-2006" TYPE="STUDY">PEDIG 2006</LINK> assessed compliance to the prescribed treatment via a parental calendar to document the number of hours of treatment. Compliance was assessed as excellent (76% to 100%) in 68% of all participants. <LINK REF="STD-PEDIG-2005" TYPE="STUDY">PEDIG 2005</LINK> assessed compliance with calendars completed weekly by the parents and by a weekly telephone call. Based on the calendars, the children randomised to receive near activities whilst undergoing occlusion spent on average 1.6 hours daily carrying out near tasks. <LINK REF="STD-PEDIG-2008" TYPE="STUDY">PEDIG 2008</LINK> also assessed compliance via parental diaries and phone calls. Of the two hours daily patching prescribed to both groups, the mean duration of occlusion was 1.9 <U>+</U> 0.2 hours per day in the distance activities group and 1.9 <U>+</U> 0.3 hours in the near activities group with 1.5 <U>+</U> 0.4 hours spent carrying out near activities.</LI>
</UL>
<P>No studies were found that investigated the cost-effectiveness of treatment or looked at the factors that affected the quality of life of the participants.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-04 15:13:56 +0000" MODIFIED_BY="Anupa Shah">
<IMPLICATIONS_PRACTICE MODIFIED="2009-11-04 15:11:57 +0000" MODIFIED_BY="Anupa Shah">
<P>The lack of multiple RCTs for the treatment of strabismic amblyopia makes it difficult to evaluate many areas of treatment. The data included in this review demonstrates that occlusion with necessary refractive correction is more effective than glasses alone for the treatment of strabismic amblyopia. The additional benefit of carrying out near activities whilst undergoing occlusion therapy is unconvincing and it is possible that the same results may be achieved by a concentrated visual effort regardless of the distance.</P>
<P>For clinicians, patients and care-givers, it would be of benefit to have a more comprehensive, evidence-based, management regime for optimal treatment outcomes for strabismic amblyopia, but at present the evidence to support such a framework does not exist.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-04 15:13:56 +0000" MODIFIED_BY="Anupa Shah">
<P>There is a need for good quality trials to be conducted in this area to improve the evidence base for the management of strabismic amblyopia. Areas specifically that require more study include:<BR/>
<BR/>1. Identification of factors affecting success of occlusion treatment, such as:<BR/>a. Age of onset of strabismus;<BR/>b. Age of commencement of treatment;<BR/>c. Starting visual acuity;<BR/>d. Compliance with treatment.</P>
<P>2. Investigation into the effectiveness of partial occlusion and optical penalisation.</P>
<P>3. Establishing overall impact of treatment:<BR/>a. Effect on psycho-social and emotional well-being of the child;<BR/>b. Non-concordance with therapy - causes, effects, measures to reduce.<BR/>c. Cost-effectiveness of treatment.</P>
<P>4. Long-term follow-up data assessing reoccurrence rates and sustainability of vision following treatment for amblyopia.</P>
<P>Varying outcome measures and review time scales make the review of trials in this area of clinical practice problematic. Trials report varying follow up times from immediately post-treatment to several months afterwards. Treatment duration also often varies. By assessing outcomes immediately post-treatment, treatment gains can be measured to show how effective a particular treatment is. By assessing outcomes one year post-treatment, recurrence rates can be established as well as the long-term visual stability of treated amblyopia. This information would be very useful for clinicians treating strabismic amblyopia.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-06-27 10:27:18 +0100" MODIFIED_BY="Anupa Shah">
<P>We acknowledge the Trials Search Co-ordinator for CEVG, for devising and running the electronic searches. We thank Anupa Shah, Managing Editor for CEVG, Sarah Hatt and the peer reviewers Catey Bunce, Stephen Gichuhi and Michael Repka for their assistance and comments. We also acknowledge the previous work carried out on this protocol by the previous authors Clare Berry (CB) and Jo Quarterly.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-07-08 20:11:05 +0100" MODIFIED_BY="Anupa  Shah">
<P>Conceiving the review: KS, CB<BR/>Designing the review: KS, SE<BR/>Co-ordinating the review: KS<BR/>Data collection for the review<BR/>- Designing search strategies: Cochrane Eyes and Vision Group<BR/>- Undertaking searches: KS, SE<BR/>- Screening search results: KS, SE<BR/>- Organising retrieval of papers: KS, SE<BR/>- Screening retrieved papers against inclusion criteria: KS, SE<BR/>- Appraising quality of papers: KS, SE<BR/>- Extracting data from papers: KS, SE<BR/>- Writing to authors of papers for additional information: KS<BR/>- Providing additional data about papers: SE<BR/>- Obtaining and screening data on unpublished studies: KS, SE<BR/>Data management for the review<BR/>- Entering data into RevMan: KS, SE<BR/>Analysis of data: KS, SE<BR/>Interpretation of data<BR/>- Providing a methodological perspective: KS, SE<BR/>- Providing a clinical perspective: KS, SE<BR/>- Providing a policy perspective: KS, SE<BR/>- Obtaining a consumer perspective: KS, SE<BR/>Writing the review: KS, SE<BR/>Providing general advice on the review: KS, SE<BR/>Updating the review: KS, SE<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-07-03 14:30:54 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-07-03 13:56:37 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-06-29 13:02:26 +0100" MODIFIED_BY="Anupa Shah">
<STUDY DATA_SOURCE="PUB" ID="STD-PEDIG-2005" MODIFIED="2011-06-29 13:01:54 +0100" MODIFIED_BY="Anupa Shah" NAME="PEDIG 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-06-29 13:01:54 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holmes JM, Edwards AR, Beck RW, Arnold RW, Johnson DA, Klimek DL, et al. Pediatric Eye Disease Investigator Group</AU>
<TI>A randomized pilot study of near activities versus non-near activities during patching therapy for amblyopia</TI>
<SO>Journal of AAPOS</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>2</NO>
<PG>129-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEDIG-2006" MODIFIED="2011-06-29 13:02:14 +0100" MODIFIED_BY="Anupa Shah" NAME="PEDIG 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-06-29 13:02:14 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace DK, Pediatric Eye Disease Investigator Group, Edwards AR, Cotter SA, Beck RW, Arnold RW, et al</AU>
<TI>A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children</TI>
<SO>Ophthalmology</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>6</NO>
<PG>904-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-PEDIG-2008" MODIFIED="2011-06-29 13:02:26 +0100" MODIFIED_BY="Anupa Shah" NAME="PEDIG 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-29 13:02:26 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pediatric Eye Disease Investigator Group</AU>
<TI>A randomized trial of near versus distance activities while patching for amblyopia in children aged 3 to less than 7 years</TI>
<SO>Ophthalmology</SO>
<YR>2008</YR>
<VL>115</VL>
<NO>11</NO>
<PG>2071-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-07-03 13:56:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Awan-2005" MODIFIED="2014-07-03 13:56:37 +0100" MODIFIED_BY="[Empty name]" NAME="Awan 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-07-03 13:56:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awan M, Proudlock FA, Gottlob I</AU>
<TI>A randomized control trial of unilateral strabismic and mixed amblyopia using occlusion dose monitor to record compliance</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>4</NO>
<PG>1435-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEDIG-2003a" MODIFIED="2011-06-29 13:02:55 +0100" MODIFIED_BY="Anupa Shah" NAME="PEDIG 2003a" YEAR="2003">
<REFERENCE MODIFIED="2011-06-29 13:02:55 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pediatric Eye Disease Investigators Group</AU>
<TI>A randomized trial of patching regimens for treatment of moderate amblyopia in children</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2003</YR>
<VL>121</VL>
<NO>5</NO>
<PG>603-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEDIG-2003b" MODIFIED="2011-06-29 13:03:03 +0100" MODIFIED_BY="Anupa Shah" NAME="PEDIG 2003b" YEAR="2003">
<REFERENCE MODIFIED="2011-06-29 13:03:03 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pediatric Eye Disease Investigator Group</AU>
<TI>A randomized trial of prescribed patching regimes for the treatment of severe amblyopia in children</TI>
<SO>Ophthalmology</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>11</NO>
<PG>2075-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEDIG-2005b" MODIFIED="2009-06-18 15:19:36 +0100" MODIFIED_BY=" Iris Gordon" NAME="PEDIG 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-06-18 15:19:36 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheiman MM, Hertle RW, Beck RW, Edwards AR, Birch E, Cotter SA, et al. Pediatric Eye Disease Investigator Group</AU>
<TI>Randomized trial of treatment of amblyopia in children aged 7 to 17 years</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2005</YR>
<VL>123</VL>
<NO>4</NO>
<PG>437-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEDIG-2007" MODIFIED="2009-06-18 16:03:15 +0100" MODIFIED_BY=" Iris Gordon" NAME="PEDIG 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-18 16:03:15 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cotter SA, Edwards AR, Arnold RW, Astle WF, Barnhardt CN, Beck RW, et al. Pediatric Eye Disease Investigator Group</AU>
<TI>Treatment of strabismic amblyopia with refractive correction</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2007</YR>
<VL>143</VL>
<NO>6</NO>
<PG>1060-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEDIG-2010" MODIFIED="2011-06-24 13:33:19 +0100" MODIFIED_BY=" Iris Gordon" NAME="PEDIG 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-24 13:33:19 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pediatric Eye Disease Investigator Group</AU>
<TI>A randomized trial comparing Bangerter filters and patching for the treatment of moderate amblyopia in children</TI>
<SO>Ophthalmology</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>5</NO>
<PG>998-1004</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-2007" MODIFIED="2011-06-29 13:03:33 +0100" MODIFIED_BY="Anupa Shah" NAME="Stewart 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-29 13:03:33 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart CE, Stephen DA, Fielder AR, Moseley MJ</AU>
<TI>Objectively monitored patching regimes for treatment of amblyopia: a randomised trial</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>335</VL>
<NO>7622</NO>
<PG>707</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-06-17 13:44:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Alotaibi-2012" MODIFIED="2014-06-17 13:44:17 +0100" MODIFIED_BY="[Empty name]" NAME="Alotaibi 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-17 13:42:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alotaibi AG, Fawazi SM, Alenazy BR, Abu-Amero KK</AU>
<TI>Outcomes of 3 hours part-time occlusion treatment combined with near activities among children with unilateral amblyopia</TI>
<SO>Saudi Medical Journal</SO>
<YR>2012</YR>
<VL>33</VL>
<NO>4</NO>
<PG>395-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-06-17 13:44:17 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-07-03 14:30:54 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-07-03 14:30:54 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ansons-2001" MODIFIED="2009-06-18 15:40:01 +0100" MODIFIED_BY=" Iris Gordon" NAME="Ansons 2001" TYPE="BOOK">
<AU>Ansons A, Davis H</AU>
<SO>Diagnosis and management of ocular motility disorders</SO>
<YR>2001</YR>
<EN>3rd</EN>
<PB>Blackwell Science Ltd</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Antonio_x002d_Santos-2014" MODIFIED="2014-07-03 14:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Antonio-Santos 2014" TYPE="COCHRANE_REVIEW">
<AU>Antonio-Santos A, Vedula SS, Hatt S, Powell C</AU>
<TI>Occlusion for stimulus deprivation amblyopia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-07-03 14:03:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-03 14:03:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005136.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Awaya-1987" MODIFIED="2009-06-18 14:07:11 +0100" MODIFIED_BY=" Iris Gordon" NAME="Awaya 1987" TYPE="CONFERENCE_PROC">
<AU>Awaya S, Miyake S, Koizumi E, Hirai T</AU>
<TI>The sensitive period of the visual system in humans</TI>
<SO>Transactions of the Sixth International Orthoptic Congress</SO>
<YR>1987</YR>
<ED>Lenek-Schafer M, Calcutt C, Doyle M, Moore S</ED>
<PB>British Orthoptic Society</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cleary-2000" MODIFIED="2009-05-13 14:15:27 +0100" MODIFIED_BY="Kate Shotton" NAME="Cleary 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cleary M</AU>
<TI>Efficacy of occlusion for strabismic amblyopia: can an optimal duration be identified?</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>6</NO>
<PG>572-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2014-07-03 14:04:24 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Epelbaum-1993" NAME="Epelbaum 1993" TYPE="JOURNAL_ARTICLE">
<AU>Epelbaum M, Milleret C, Buisseret P, Dufier JL</AU>
<TI>The sensitive period for strabismic amblyopia in humans</TI>
<SO>Ophthalmology</SO>
<YR>1993</YR>
<VL>100</VL>
<NO>3</NO>
<PG>323-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" MODIFIED="2009-05-13 14:15:37 +0100" MODIFIED_BY="Kate Shotton" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomised controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-07-03 14:05:06 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2009" MODIFIED="2014-07-03 14:23:33 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2009" TYPE="COCHRANE_REVIEW">
<AU>Li TJ, Shotton K</AU>
<TI>Conventional occlusion versus pharmacologic penalization for amblyopia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-11-05 15:50:58 +0000" MODIFIED_BY=" Iris Gordon">
<IDENTIFIER MODIFIED="2009-11-05 15:50:58 +0000" MODIFIED_BY=" Iris Gordon" TYPE="DOI" VALUE="10.1002/14651858.CD006460.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mazow-2000" MODIFIED="2009-06-18 12:09:07 +0100" MODIFIED_BY=" Iris Gordon" NAME="Mazow 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mazow MD, Chuang A, Vital MC, Prager T</AU>
<TI>1999 Costenbader Lecture. Outcome study in amblyopia: treatment and practice pattern variations</TI>
<SO>Journal of AAPOS</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mintz_x002d_Hittner-2000" MODIFIED="2009-06-18 11:24:50 +0100" MODIFIED_BY=" Iris Gordon" NAME="Mintz-Hittner 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mintz-Hittner HA, Fernandez KM</AU>
<TI>Successful amblyopia therapy initiated after age 7 years: compliance cures</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>11</NO>
<PG>1535-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mohan-2004" MODIFIED="2014-07-03 14:25:04 +0100" MODIFIED_BY="[Empty name]" NAME="Mohan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mohan K, Saroha V, Sharma A</AU>
<TI>Successful occlusion therapy for amblyopia in 11- to 15-year-old children</TI>
<SO>Journal of Pediatric Ophthalmology and Strabismus</SO>
<YR>2004</YR>
<VL>41</VL>
<NO>2</NO>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newsham-2000" MODIFIED="2009-06-18 11:18:16 +0100" MODIFIED_BY=" Iris Gordon" NAME="Newsham 2000" TYPE="JOURNAL_ARTICLE">
<AU>Newsham D</AU>
<TI>Parental non-concordance with occlusion therapy</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>9</NO>
<PG>257-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-2004" MODIFIED="2009-06-18 11:15:47 +0100" MODIFIED_BY=" Iris Gordon" NAME="Park 2004" TYPE="JOURNAL_ARTICLE">
<AU>Park KH, Hwang JM, Ahn JK</AU>
<TI>Efficacy of amblyopia therapy initiated after 9 years of age</TI>
<SO>Eye</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>6</NO>
<PG>571-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rahi-2002" MODIFIED="2009-06-18 11:15:29 +0100" MODIFIED_BY=" Iris Gordon" NAME="Rahi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rahi JS, Logan S, Timms C, Russell-Eggitt I, Taylor D</AU>
<TI>Risk, causes, and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population based study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9333</NO>
<PG>597-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCOphth-2002" MODIFIED="2009-09-29 13:06:43 +0100" MODIFIED_BY="Anupa Shah" NAME="RCOphth 2002" TYPE="OTHER">
<AU>The Royal College of Ophthalmologists</AU>
<TI>Guidelines for the management of strabismus and amblyopia in childhood</TI>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2014-07-03 11:45:32 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowe-2004" MODIFIED="2011-06-24 15:41:00 +0100" MODIFIED_BY=" Iris Gordon" NAME="Rowe 2004" TYPE="BOOK">
<AU>Rowe F</AU>
<SO>Clinical orthoptics</SO>
<YR>2004</YR>
<EN>2nd</EN>
<PB>Blackwell Publishing Ltd</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-2004" MODIFIED="2009-06-18 11:09:05 +0100" MODIFIED_BY=" Iris Gordon" NAME="Stewart 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stewart CE, Moseley MJ, Fielder AR, Stephens DA. MOTAS Cooperative</AU>
<TI>Refractive adaptation in amblyopia: quantification of effect and implications for practice</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2004</YR>
<VL>88</VL>
<NO>12</NO>
<PG>1552-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2003" MODIFIED="2009-06-18 15:31:39 +0100" MODIFIED_BY=" Iris Gordon" NAME="Tan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tan JH, Thompson JR, Gottlob I</AU>
<TI>Differences in the management of amblyopia between European countries</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>87</VL>
<NO>3</NO>
<PG>291-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1995" MODIFIED="2011-06-24 13:41:23 +0100" MODIFIED_BY=" Iris Gordon" NAME="Taylor 1995" TYPE="OTHER">
<AU>Taylor JF</AU>
<TI>Medical aspects of fitness to drive. A guide for medical practitioners</TI>
<SO>Medical Committee of Accident Prevention</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2012" MODIFIED="2014-07-03 14:30:54 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor 2012" TYPE="COCHRANE_REVIEW">
<AU>Taylor K, Powell C, Hatt SR, Stewart C</AU>
<TI>Interventions for unilateral and bilateral refractive amblyopia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-07-03 14:30:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-03 14:30:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005137.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-07-03 13:54:20 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Shotton-2007" MODIFIED="2014-07-03 13:45:31 +0100" MODIFIED_BY="[Empty name]" NAME="Shotton 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Shotton K, Elliott S</AU>
<TI>Interventions for strabismic amblyopia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-07-03 13:44:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-03 13:44:54 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006461"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shotton-2008a" MODIFIED="2014-07-03 13:52:05 +0100" MODIFIED_BY="[Empty name]" NAME="Shotton 2008a" TYPE="COCHRANE_REVIEW">
<AU>Shotton K, Elliott S</AU>
<TI>Interventions for strabismic amblyopia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-07-03 13:51:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-03 13:51:29 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006461.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2011" MODIFIED="2014-07-03 13:54:20 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor 2011" TYPE="COCHRANE_REVIEW">
<AU>Taylor K, Elliott S</AU>
<TI>Interventions for strabismic amblyopia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2014-07-03 13:54:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-03 13:54:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006461.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-07-16 19:17:42 +0100" MODIFIED_BY="Anupa  Shah">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-11-06 14:07:23 +0000" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-11-02 16:25:33 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-PEDIG-2005">
<CHAR_METHODS MODIFIED="2009-11-02 16:25:33 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised into treatment or control group via study website. Treatment outcome masked. No participant was excluded after randomisation. Only 3 participants were lost to follow-up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-08 14:21:23 +0100" MODIFIED_BY="Kate Shotton">
<P>All participants were enrolled within the United States. All participants aged between 3 and 7 years. The inclusion criteria were presence of manifest squint and VA in the amblyopic eye of 20/40 to 20/400 (6/12 to 6/120, 0.300 to 1.00). All participants were to undergo 2 hours daily occlusion. Participants were excluded if they had undergone any amblyopia treatment in the month previous to the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 12:43:50 +0100" MODIFIED_BY="Kate Shotton">
<P>Treatment group: 2 hours daily occlusion with near activities.<BR/>Control group: 2 hours daily occlusion with non-near activities.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Visual acuity in amblyopic eye at 4 week assessment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-06 14:07:10 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-PEDIG-2006">
<CHAR_METHODS MODIFIED="2009-11-04 15:18:27 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised into treatment or control group via study website. Outcome of treatment analysed masked. No participant was excluded after randomisation. Only 3 participants were lost to follow-up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-05 14:42:29 +0100" MODIFIED_BY="[Empty name]">
<P>All participants were enrolled within the United States. All participants aged between 3 and 7 years. The inclusion criteria were presence of manifest squint and visual acuity in the amblyopic eye of 20/40 to 20/400 (6/12 to 6/120, 0.300 to 1.000). Participants were excluded if they had undergone any amblyopia treatment in the month prior to the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment group: 2 hours daily occlusion <BR/>Control group: observation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-06 14:07:10 +0000" MODIFIED_BY="Anupa Shah">
<P>Visual acuity in amblyopic eye at end of trial.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-06 14:07:23 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-PEDIG-2008">
<CHAR_METHODS MODIFIED="2009-08-05 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised into treatment or control group via study website. Treatment outcome masked. No participant was excluded after randomisation. 27 participants were lost to follow-up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-05 14:42:44 +0100" MODIFIED_BY="[Empty name]">
<P>All participants were enrolled within the United States. All participants aged between 3 and 7 years. The inclusion criteria were presence of manifest squint and VA in the amblyopic eye of 20/40 to 20/400 (6/12 to 6/120, 0.300 to 1.00). All participants were to undergo 2 hours daily occlusion. Participants were excluded if they had undergone any amblyopia treatment in the 6 months prior to the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-11 09:12:44 +0100" MODIFIED_BY="Kate Shotton">
<P>Treatment group: 2 hours daily occlusion with near activities.<BR/>Control group: 2 hours daily occlusion with distance activities.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-06 14:07:23 +0000" MODIFIED_BY="Anupa Shah">
<P>Visual acuity in the amblyopic eye at 8 week masked visit.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-06-27 10:09:01 +0100" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-05 14:44:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Awan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 14:44:57 +0100" MODIFIED_BY="[Empty name]">
<P>This randomised trial investigates compliance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-29 12:49:10 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-PEDIG-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-29 12:49:10 +0100" MODIFIED_BY="Anupa Shah">
<P>This randomised trial reviews 2 hours versus 6 hours occlusion for moderate amblyopia. The role of this review is not to establish the most effective part-time occlusion regime.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 14:44:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PEDIG-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 14:44:05 +0100" MODIFIED_BY="[Empty name]">
<P>This randomised trial reviews 6 hours daily occlusion to 12 hours daily occlusion for severe amblyopia. It is not the role of this review to compare occlusion regimes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 14:45:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PEDIG-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 14:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>This randomised trial compares occlusion therapies, including a pharmacological intervention, in older children. All pharmacological treatments will be covered in a separate Cochrane review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-PEDIG-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>The paper presents case reports of the treatment of strabismic amblyopia and is not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-27 10:09:01 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-PEDIG-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-27 10:09:01 +0100" MODIFIED_BY="Anupa Shah">
<P>This trial compares two treatment regimes; Bangerter filters and occlusion. It is not within the scope of this review to compare these two interventions to one another.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 14:45:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stewart-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 14:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>This randomised trial compares 6 hours daily occlusion to 12 hours daily occlusion. The aim of this review is not to compare occlusion regimes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-07-16 19:17:42 +0100" MODIFIED_BY="Anupa  Shah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-07-16 19:17:42 +0100" MODIFIED_BY="Anupa  Shah" STUDY_ID="STD-Alotaibi-2012">
<CHAR_METHODS MODIFIED="2014-07-16 19:16:30 +0100" MODIFIED_BY="Anupa  Shah">
<P>Part-time occlusion carried out by all trial participants. One group recommended to undertake 3 hours of near activities whilst wearing occlusion (such as reading), the other group advised not to do any near tasks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-16 19:16:29 +0100" MODIFIED_BY="Anupa  Shah">
<P>The study was carried out in the Pediatric Ophthalmology and Orthoptics Clinics of King Abdul-Aziz University Hospital, Riyadh, Saudi Arabia for the period from January to November 2010. One hundred and thirty participants were followed-up for a 12-week period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-15 09:10:33 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: 3 hours daily occlusion with near activities.<BR/>Control group: 3 hours daily occlusion with non-near activities.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-16 19:17:42 +0100" MODIFIED_BY="Anupa  Shah">
<P>Main outcome measures were best-corrected visual acuity for both groups and line improvement.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-16 19:17:05 +0100" MODIFIED_BY="Anupa  Shah">
<P>Unclear method of group selection/randomisation. Authors contacted March 2014 for further details. No response received as yet. Details will be updated should more information become available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-11-06 14:07:17 +0000" MODIFIED_BY="Anupa Shah">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-04-08 16:31:11 +0100" MODIFIED_BY="Kate Shotton" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:23:26 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2005">
<DESCRIPTION>
<P>Sequence was computer generated using a permuted block design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:29:32 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2006">
<DESCRIPTION>
<P>Sequence was computer generated using a permuted block design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:31:11 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2008">
<DESCRIPTION>
<P>Sequence was computer generated using a permuted block design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-11-02 16:26:18 +0000" MODIFIED_BY="Anupa Shah" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-02 16:25:36 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-PEDIG-2005">
<DESCRIPTION>
<P>Allocation via study website after recruitment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-02 16:26:18 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-PEDIG-2006">
<DESCRIPTION>
<P>Allocation via study website after recruitment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-05 14:42:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PEDIG-2008">
<DESCRIPTION>
<P>Allocation via study website after recruitment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-11-02 16:26:28 +0000" MODIFIED_BY="Anupa Shah" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-02 16:25:57 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-PEDIG-2005">
<DESCRIPTION>
<P>Masked examiners carried out vision testing. No documented reports of masking being breached.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-23 19:10:12 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-PEDIG-2006">
<DESCRIPTION>
<P>Masked examiners carried out vision testing. Percentage of occasions when the masking was breached is published; 5% in the patching group, 1% in the control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-02 16:26:28 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-PEDIG-2008">
<DESCRIPTION>
<P>Masked examiners carried out vision testing. Percentage of occasions when the masking was breached is published; 3% in the patching group, 3% in the control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-11-06 14:07:17 +0000" MODIFIED_BY="Anupa Shah" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-02 16:26:14 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-PEDIG-2005">
<DESCRIPTION>
<P>Similar rates of follow-up in both treatment groups. Main outcome measure was completed by 94% in treatment group and 88% in control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-06 14:07:17 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-PEDIG-2006">
<DESCRIPTION>
<P>Similar rates of follow-up in both treatment groups. Main outcome measure was completed by 98% in treatment group and 95% in control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-02 16:26:36 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-PEDIG-2008">
<DESCRIPTION>
<P>Similar rates of follow-up in both treatment groups. Main outcome measure was completed by 92% in treatment group and 95% in control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-04-08 16:31:46 +0100" MODIFIED_BY="Kate Shotton" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:28:33 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2005">
<DESCRIPTION>
<P>Study protocol is published and outcomes are reported as pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:30:46 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2006">
<DESCRIPTION>
<P>Study protocol is published and outcomes are reported as pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:31:46 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2008">
<DESCRIPTION>
<P>Study protocol is published and outcomes are reported as pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-04-08 16:31:38 +0100" MODIFIED_BY="Kate Shotton" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:28:53 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2005">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:30:59 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2006">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:31:38 +0100" MODIFIED_BY="Kate Shotton" RESULT="YES" STUDY_ID="STD-PEDIG-2008">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-04-08 16:32:44 +0100" MODIFIED_BY="Kate Shotton"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-08-17 16:18:42 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-05-13 12:04:02 +0100" MODIFIED_BY="Kate Shotton" NO="1">
<NAME>Occlusion with near activities versus occlusion with non-near activities</NAME>
<CONT_OUTCOME CHI2="0.6444487508881444" CI_END="0.05298452079194435" CI_START="-0.10568556882315708" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.026350524015606367" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2009-05-13 12:04:02 +0100" MODIFIED_BY="Kate Shotton" NO="1" P_CHI2="0.42210467327156775" P_Q="1.0" P_Z="0.5150549215571288" Q="0.0" RANDOM="NO" SCALE="1.12" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="73" UNITS="" WEIGHT="100.0" Z="0.6509869398779344">
<NAME>Mean visual acuity at cessation of treatment</NAME>
<GROUP_LABEL_1>Treatment (near)</GROUP_LABEL_1>
<GROUP_LABEL_2>Control (non-near)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.18957906150552817" CI_START="-0.5295790615055282" EFFECT_SIZE="-0.17000000000000004" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.55" ORDER="44242" SD_1="0.17" SD_2="0.5" SE="0.1834620760084583" STUDY_ID="STD-PEDIG-2005" TOTAL_1="12" TOTAL_2="8" WEIGHT="4.867896699077085"/>
<CONT_DATA CI_END="0.062339504407134566" CI_START="-0.10033950440713449" EFFECT_SIZE="-0.01899999999999996" ESTIMABLE="YES" MEAN_1="0.331" MEAN_2="0.35" MODIFIED="2009-04-29 16:12:18 +0100" MODIFIED_BY="Kate Shotton" ORDER="3" SD_1="0.23" SD_2="0.243" SE="0.04150050972810223" STUDY_ID="STD-PEDIG-2008" TOTAL_1="65" TOTAL_2="65" WEIGHT="95.13210330092292"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Conventional part-time occlusion versus observation</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean visual acuity at cessation of treatment</NAME>
<GROUP_LABEL_1>Treatment (2 hrs)</GROUP_LABEL_1>
<GROUP_LABEL_2>Control (gls)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.03611660862735608" CI_START="-0.3238833913726439" EFFECT_SIZE="-0.18" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="0.51" ORDER="44243" SD_1="0.15" SD_2="0.29" SE="0.07341124250627958" STUDY_ID="STD-PEDIG-2006" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-07-03 14:39:03 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-07-03 14:39:03 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Results from searching for studies for inclusion in the review</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAt8AAAL4CAYAAACjo5tKAAB1HUlEQVR42uydD2SX6///P0ySmYlM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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-03 11:59:01 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-07-03 11:58:57 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAREAAAF0CAIAAACLz5owAAANDUlEQVR42u3dsc4dNRPG8fcCUlDk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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-07-01 16:36:02 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-06-18 09:31:54 +0100" MODIFIED_BY=" Iris Gordon" NO="1">
<TITLE MODIFIED="2009-06-18 09:31:54 +0100" MODIFIED_BY=" Iris Gordon">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-18 17:18:25 +0100" MODIFIED_BY="Anupa Shah">
<P>#1 MeSH descriptor Strabismus<BR/>#2 strabism*<BR/>#3 squint*<BR/>#4 (#1 OR #2 OR #3)<BR/>#5 MeSH descriptor Amblyopia<BR/>#6 amblyop*<BR/>#7 (#5 OR #6)<BR/>#8 (#4 AND #7)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-07-01 16:35:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-07-01 16:35:16 +0100" MODIFIED_BY="[Empty name]">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-12 12:30:45 +0100" MODIFIED_BY="[Empty name]">
<P>1 randomised controlled trial.pt.<BR/>2 (randomised or randomised).ab,ti.<BR/>3 placebo.ab,ti.<BR/>4 dt.fs.<BR/>5 randomly.ab,ti.<BR/>6 trial.ab,ti.<BR/>7 groups.ab,ti.<BR/>8 or/1-7<BR/>9 exp animals/<BR/>10 exp humans/<BR/>11 9 not (9 and 10)<BR/>12 8 not 11<BR/>13 exp strabismus/<BR/>14 strabism$.tw.<BR/>15 squint$.tw.<BR/>16 or/13-15<BR/>17 exp amblyopia/<BR/>18 amblyop$.tw.<BR/>19 or/17-18<BR/>20 16 and 19<BR/>21 12 and 20</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-07-01 16:35:30 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-07-01 16:35:30 +0100" MODIFIED_BY="[Empty name]">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-13 12:44:28 +0100" MODIFIED_BY="Kate Shotton">
<P>1 exp randomised controlled trial/<BR/>2 exp randomisation/<BR/>3 exp double blind procedure/<BR/>4 exp single blind procedure/<BR/>5 random$.tw.<BR/>6 or/1-5<BR/>7 (animal or animal experiment).sh.<BR/>8 human.sh.<BR/>9 7 and 8<BR/>10 7 not 9<BR/>11 6 not 10<BR/>12 exp clinical trial/<BR/>13 (clin$ adj3 trial$).tw.<BR/>14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.<BR/>15 exp placebo/<BR/>16 placebo$.tw.<BR/>17 random$.tw.<BR/>18 exp experimental design/<BR/>19 exp crossover procedure/<BR/>20 exp control group/<BR/>21 exp latin square design/<BR/>22 or/12-21<BR/>23 22 not 10<BR/>24 23 not 11<BR/>25 exp comparative study/<BR/>26 exp evaluation/<BR/>27 exp prospective study/<BR/>28 (control$ or prospectiv$ or volunteer$).tw.<BR/>29 or/25-28<BR/>30 29 not 10<BR/>31 30 not (11 or 23)<BR/>32 11 or 24 or 31<BR/>33 exp strabismus/<BR/>34 strabism$.tw.<BR/>35 squint$.tw.<BR/>36 or/33-35<BR/>37 exp amblyopia/<BR/>38 amblyop$.tw.<BR/>39 or/37-38<BR/>40 36 and 39<BR/>41 32 and 40</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-06-18 09:32:53 +0100" MODIFIED_BY=" Iris Gordon" NO="4">
<TITLE MODIFIED="2009-06-18 09:32:53 +0100" MODIFIED_BY=" Iris Gordon">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-18 17:18:20 +0100" MODIFIED_BY="Anupa Shah">
<P>strabism$ or squint$ and amblyop$</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-07-01 16:36:02 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-07-01 16:36:02 +0100" MODIFIED_BY="[Empty name]">
<I>meta</I>Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-24 12:59:55 +0100" MODIFIED_BY=" Iris Gordon">
<P>strabismus and amblyopia</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2011-06-24 13:00:10 +0100" MODIFIED_BY=" Iris Gordon" NO="6">
<TITLE MODIFIED="2011-06-24 12:59:07 +0100" MODIFIED_BY=" Iris Gordon">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-24 13:00:10 +0100" MODIFIED_BY=" Iris Gordon">
<P>Strabismus AND Amblyopia</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2014-07-01 16:34:42 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2014-07-01 16:30:25 +0100" MODIFIED_BY="[Empty name]">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-01 16:34:42 +0100" MODIFIED_BY="[Empty name]">
<P>Strabismus AND Amblyopia</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in quantitative synthesis&lt;/p&gt;" WIDTH="212">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in qualitative synthesis &lt;/p&gt;" WIDTH="209">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in previous version of the review (searches as of June 2011) &lt;/p&gt;" WIDTH="210"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 full-text report assessed for eligibility. The report contained insufficient information to assess if the trial is eligible for inclusion. The authors have been contacted but no response has been received&lt;/p&gt;" WIDTH="207">
<FLOWCHARTBOX TEXT="&lt;p&gt;51 records screened by the authors&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;208 records screened by the Trials Search Co-ordinator (TSC) &lt;/p&gt;" WIDTH="212">
<FLOWCHARTBOX TEXT="&lt;p&gt;208 records after duplicates removed&lt;/p&gt;" WIDTH="210">
<FLOWCHARTBOX TEXT="&lt;p&gt;276 records identified through electronic database searching (June 2011 to January 2014) &lt;/p&gt;" WIDTH="222"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;157 records excluded by the TSC after initial screening&lt;/p&gt;" WIDTH="186"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;50 records excluded by the authors as not relevant&lt;/p&gt;" WIDTH="193"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>